ReviewOncology letters2025
Diagnostic methods for pancreatic cancer and their clinical applications (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacological activity, molecular mechanisms and therapeutic potential of erianin (Review).International journal of molecular medicine · 2026Review
- Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is often considered one of the most aggressive and deadly types of cancer, distinguished by its swift advancement and unfavorable prognosis. This reality highlights the vital necessity for early detection to improve patient survival rates. In recent years, notable advancements in medical technology have catalyzed the development of various diagnostic approaches, including imaging modalities, tumor markers, tissue biopsy, liquid biopsy, volatile organic compounds and nanomaterials. However, despite the promising progress in these diagnostic tools, numerous challenges persist, particularly concerning the sensitivity and specificity of these methods, as well as the complexities involved in their practical implementation in everyday clinical practice. The present review article aims to produce a thorough analysis of the applicability of each diagnostic method available for PC, highlighting their respective strengths and limitations while providing clinical recommendations aimed at enhancing the early identification of this formidable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.